Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma

NCT01474239 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01474239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01474239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2011
Completion date
December 31, 2013
Enrollment
91 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma multiforme